tbuckley/cabot-search huggingface dataset:
Imatinib 400mg Daily Combined with Vindesine and Dexamethasone As Induction and Maintenance Therapy for Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Authors: Ting Liu, Pu Kuang, Tian Dong, Bing Xiang, Jianjun Li, Xinchuan Chen, Chuan He, Hongbing Ma, Jie Ji, Yuping Gong, Hong Chang, Yu Wu, Huanling Zhu, Yuchun Wang
Journal: Blood (2011)
One year cancer survival index rises in England
Authors: Susan Mayor
Journal: BMJ (2016)

The one year survival index among patients with all types of cancer in England has increased steadily over the past 15 years, and variations around the country have decreased, the Office for National Statistics has reported.1

Latest figures show that the one year cancer survival index increased from 60.6% in people with cancer diagnosed in 1999 to 70.4% in those with cancer diagnosed in 2014. The index represents an average of all cancer survival estimates by age, sex, and cancer type and is …
Sick leave in patients with prostate cancer before, during, and after radiotherapy.
Authors: Joen Sveistrup, Peter Meidahl Petersen, Ole Steen Mortensen, Svend Aage Engelholm
Journal: Journal of Clinical Oncology (2012)

153 Background: Returning to work following cancer treatment is a sign of recovery. Side-effects might result in sick leave rendering patients unable to work. The purpose of this study was to determine the pattern of sick leave in patients with prostate cancer (PCa) before, during and after definitive radiotherapy. Methods: The Danish DREAM-database contains information on all social benefits paid out to Danish citizens. Based on the DREAM-database it is possible to assess whether a patient is working, on sick leave, or retired. Data on 427 of 473 Danish citizens, treated with definitive intensity-modulated radiotherapy for PCa at our center between January 1 2005 and May 1 2010, were obtained from the DREAM-database. Of the 427 patients 118 patients were working or available to the job market at the start of radiotherapy. Of the 118 patients 59 patients were on sick leave at some point during the course of radiotherapy and they followed in the DREAM-database from one year prior to radiotherapy until one year after the treatment. The median age was 60 (age, range 49–65). Based on the data from the database the 59 patients were divided into the four categories “Working or unemployed”, “Sick leave”, “Retirement” or “Dead”. Furthermore, the patients’ statuses after sick leave were determined. Results: The results are shown in the table. Nearly all patients (91.5%) return to work following sick leave. One year after radiotherapy 64.4% of the patients are working, and 13.6% are on sick leave. Conclusions: The vast majority of patients that are on sick leave during the course of radiotherapy for PCa return to work. However, one year after RT only 64 % are working or available for work indicating that the return to work for a lot of the patients is relatively short-lasting. Further research is needed to clarify why. [Table: see text]
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303.
Authors: A. B. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. Hurwitz
Journal: Journal of Clinical Oncology (2011)

10508 Background: CALGB 80303 was a phase III trial of 602 patients (pts) with locally advanced or metastatic pancreatic cancer (PC) comparing gemcitabine + bevacizumab (GB) vs. gemcitabine + placebo (GP). That study found no overall survival (OS) benefit from the addition of B. Blood samples were collected for prospective biomarker analyses. Methods: Plasma samples were analyzed via a novel multiplex ELISA platform for >40 candidate factors related to tumor growth, angiogenesis, and inflammation. This platform was optimized for use in cancer patients. Baseline values were correlated with OS using univariate Cox proportional hazard regression models and multivariate Cox models with leave-one-out cross validation (LOOCV). Potential predictive markers were identified using a treatment by marker interaction term in the Cox model. Results: 328 pts had baseline samples available. Univariate prognostic markers predicting OS identified within the GB and GP cohorts included: Ang2, CRP, ICAM-1, IGFBP-1, TSP-2 (all p<0.001). By multivariate analysis, these markers were significantly more prognostic than standard clinical factors, such as age, gender, extent of disease and performance status. LOOCV modeling yielded consistent multivariate prognostic signatures that differentiated patients with longer vs. shorter survival. The signature for the GB group consisted of IGFBP-1, IL-6, PDGF-AA, PDGF-BB, TSP-2; while the signature for the GP group consisted of CRP, IGFBP-1, PAI-1, PDGF-AA, PEDF (both p<0.0001). Three potential predictive markers of superior OS for GB vs. GP were identified: VEGF-D (p<0.01), SDF-1b (p<0.05), and Ang2 (p<0.05). Spearman's rank correlation coefficients suggested that many factors were co-regulated. Conclusions: This is one of the first phase III studies to report multiplex angiome profiling and it shows that tumor angiogenesis factors are highly prognostic in patients with PC. Several of these factors may define those pts more or less likely to benefit from the addition of B to G. This information should allow better stratification of patients with PC and may guide novel therapeutic interventions in PC and perhaps other cancers.
Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program
Authors: Edward A. Copelan, Jonathan M. Gerber, Saad Z Usmani, Michael R. Grunwald, Nilanjan Ghosh, Omotayo O. Fasan, Manisha Bhutani, James T Symanowski, Derek Raghavan, Belinda R. Avalos
Journal: Blood (2016)
Effect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo.
Authors: R. Rota, L. Raimondi, R. Ciarapica, F. Verginelli, M. Gueguen, R. Boldrini, L. De Sio, A. Inserra, M. Locatelli, T. Dang, L. Miele, S. Stifani, I. Limon, F. Locatelli
Journal: Journal of Clinical Oncology (2011)

10068 Background: Rhabdomyosarcoma is a pediatric soft tissue sarcoma that originates from skeletal muscle progenitors that proliferate indefinitely. Notch signaling inhibits myogenesis and has been reported to be abnormally activated in rhabdomyosarcomas. However, the mechanism underlying the deregulation of Notch signaling in rhabdomyosarcoma remains unclear. Methods: The activation of Notch signaling was investigated in primary rhabdomyosarcomas and cell lines. The role of Notch was evaluated through gene silencing in tumor cell lines in vitro and on a xenografts model in vivo. Results: Notch3 and Notch1 were over-expressed and activated in rhabdomyosarcoma cell lines when compared to cultured myoblasts. Moreover, they were over-expressed, along with their target gene HES1, in a cohort of 5 fusion-positive and 24 fusion-negative rhabdomyosarcoma primary samples as compared to skeletal muscle tissues. Notch3 expression was significantly higher in rhabdomyosarcoma specimens with respect to Notch1, irrespective to the fusion-gene status (P<0.05). Furthermore, in the whole cohort, patients with HES1 expression levels over the median value showed poor overall survival and shorter recurrence free interval (P=0.0001 for both). Notch3 targeted down-regulation severely impaired proliferation of both alveolar and embryonal rhabdomyosarcoma cell lines hampering their tumorigenic properties in vitro and tumor xenografts growth in vivo. Conclusions: Altogether, these results support a role for Notch3 as an inhibitor of differentiation in rhabdomyosarcoma and identify the Notch3 signaling pathway as a new potential target for therapy in this soft tissue sarcoma.
Target Transplantation of Mesenchymal Stem Cells into the Murine Femur to Support Hematopoiesis By Magic-TT: Both In Vivo and in Vitro Studies
Authors: Qianli Jiang, Hao Huang, Yongjun Zhou, Qiuxia Zhang, Xiaowei Sun, Minchun Zhang, Yanyan Ye, Zhihao Zheng, Kaifeng Ye, Kitbok Majaw Jerry, Jing Sun, Qifa Liu
Journal: Blood (2015)
Endoscopic ultrasound-guided fine needle core biopsy versus aspiration for gastrointestinal mass lesions: A randomized trial.
Authors: Nam Q. Nguyen
Journal: Journal of Clinical Oncology (2012)

161 Background: Endoscopic ultrasound (EUS) guided biopsy allows cytologic and/or histologic diagnosis of lesions within or adjacent to the gastrointestinal tract (GIT). However, the amount of tissue obtained with a regular aspirating needle is not always satisfactory. A newly developed Coo Pro-Core 22G needle has been proposed to obtain core tissue and may improve diagnostic yield. This study aimed to compare the performance of two EUS guided biopsy systems, Coo 22G fine needle aspiration (FNA) versus Coo 22G Pro-Core (PC) needle, in the evaluation of mass lesions within or adjacent to the GIT. Methods: 61 consecutive patients, who were referred for EUS guided biopsy of mass lesions within or adjacent to the upper GIT, were randomized to either the use of 22G FNA or 22G PC needle. The procedures were performed by a single experienced EUS-endoscopist. Four needle passes were taken from each lesion and all specimens were prepared as cell-block for histo-cytological analysis. Measured outcomes were diagnostic yield and complication. Results: EUS guided biopsy was performed with 22G FNA needle in 31patients and with 22G PC needle in 30 patients. There were no differences in age, gender, site or size of biopsied lesion between the groups. Diagnostic yield from the PC group was significantly higher than that of the FNA groups (27/30 vs. 22/31, P=0.04). The ability to obtain core-like tissue and provide “histological” detail were also higher in the PC group (16/30 vs. 0/31, P&lt;0.001). Although no patients with FNA biopsy had complications, the first 4 cases of PC needle biopsy had abdominal pain (with 1 proven pancreatitis), requiring overnight admission. No further complications occurred after the number of PC passes was reduced to 2 per lesion. Conclusions: EUS guided biopsy with Pro-Core needles had a substantially higher diagnostic yield than that with FNA needles, with the ability to provide "histological" information in the majority of cases. Initial use of the Pro-Core needle, however, is associated with an increased risk of abdominal pain, which is reduced with fewer passes and more experience.
Impact of Comorbidities on the Outcome of Elderly Patients with Acute Myeloid Leukemia.
Authors: Anne Etienne, Benjamin Esterni, Aude Charbonnier, Thomas Prébet, Diane Coso, Anne-Marie Stoppa, Evelyne D’Incan, Marie-Françoise Doglio, Danièle Sainty, Christine Arnoulet, Marie-Joëlle Mozziconacci, Jean-Albert Gastaut, Norbert Vey
Journal: Blood (2006)
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery
Authors: Monica Civallero, Viviana Vergaro, Cinzia Citti, Maria Cosenza, Giuseppe Cannazza, Carlo Parenti, Alessia Bari, Giuseppe Ciccarella, Stefano Sacchi, Samantha Pozzi
Journal: Blood (2015)
Reflections on the national patient-reported outcome measures (PROMs) programme: Where do we go from here?
Authors: Derek Kyte, Paul Cockwell, Mauro Lencioni, Magdalena Skrybant, Maria von Hildebrand, Gary Price, Katie Squire, Shena Webb, Olivia Brookes, Hilary Fanning, Tim Jones, Melanie Calvert
Journal: Journal of the Royal Society of Medicine (2016)
Personal preferences and treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer.
Authors: Jaclyn Lee Fong Bosco, Barbara Halpenny, Donna Lynn Berry
Journal: Journal of Clinical Oncology (2012)

170 Background: Men diagnosed with localized prostate cancer (LPC) can choose from multiple treatment regimens and are faced with a decision in which medical factors and personal preferences are important. The Personal Patient Profile-Prostate (P3P) is a computerized decision aid for men with LPC that focuses on personal preferences. We determined the proportion of men with LPC who chose a concordant treatment approach by 6-months with self-reported, influential side effects by intervention or control group, and evaluated whether the intervention (versus control) group was more likely to choose a concordant treatment. Methods: English or Spanish-speaking men diagnosed with LPC (2007–2009) from four US cities were enrolled into a randomized trial and followed at 1- and 6-months via mailed or online questionnaire. Men were randomized to receive the P3P intervention or standard education plus links to reputable websites (control group). We classified concordance as men who were (a) concerned with urinary incontinence and/or erectile dysfunction and chose radiotherapy, (b) concerned with bowel dysfunction and chose prostatectomy, (c) concerned with all three side effects and chose watchful waiting, or (d) not concerned with any side effect and chose any treatment. We calculated the proportion of concordance by group. Using logistic regression, we calculated odds ratios (OR) and 95% confidence intervals (CI) for the association between the P3P intervention and concordance. Results: Of 448 men, most were &lt;65 years, non-Hispanic white, and had multiple physician consultations prior to study enrollment. Only 43% of the sample chose a concordant treatment given concerns about potential side effects. There was no significant difference in concordance between the intervention (43%) and control (42%) group (OR=1.1; 95%CI=0.73, 1.7). Conclusions: The P3P intervention was not associated with concordance between potential side effects and treatment choice. Information and/or physician consultation immediately after diagnosis was likely to influence decisions despite concerns about side effects. The intervention may be more effective before the first treatment options consultation.
Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group.
Authors: Noelia Purroy, Andrés López, Teresa Vallespi, Mercedes Gironella, Juan Bergua, Juan Manuel Sancho
Journal: Blood (2009)
Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension
Authors: Tufik R. Assad, Anna R. Hemnes, Emma K. Larkin, Andrew M. Glazer, Meng Xu, Quinn S. Wells, Eric H. Farber-Eger, Quanhu Sheng, Yu Shyr, Frank E. Harrell, John H. Newman, Evan L. Brittain
Journal: Journal of the American College of Cardiology (2016)
Higher Cell Dose and CD34+ Content Improves Engraftment Following Unrelated Donor Cord Blood Transplantation (CBT): A Report of the National Marrow Donor Program (NMDP) Cord Blood (CB) Experience.
Authors: Donna Wall, John Wagner, Mary Laughlin, Karen Ballen, Susan Staba, Ka Wah Chan, Olivia McGaha, Brent Logan, John Klein, Mukta Arora
Journal: Blood (2004)
MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol
Authors: Masataka Nishiga, Takahiro Horie, Yasuhide Kuwabara, Kazuya Nagao, Osamu Baba, Tetsushi Nakao, Tomohiro Nishino, Daihiko Hakuno, Yasuhiro Nakashima, Hitoo Nishi, Fumiko Nakazeki, Yuya Ide, Satoshi Koyama, Masahiro Kimura, Ritsuko Hanada, Tomoyuki Nakamura, Tsukasa Inada, Koji Hasegawa, Simon J. Conway, Toru Kita, Takeshi Kimura, Koh Ono
Journal: Circulation Research (2016)

Heart failure and atherosclerosis share the underlying mechanisms of chronic inflammation followed by fibrosis. A highly conserved microRNA (miR), miR-33, is considered as a potential therapeutic target for atherosclerosis because it regulates lipid metabolism and inflammation. However, the role of miR-33 in heart failure remains to be elucidated.To clarify the role of miR-33 involved in heart failure.We first investigated the expression levels of miR-33a/b in human cardiac tissue samples with dilated cardiomyopathy. Increased expression of miR-33a was associated with improving hemodynamic parameters. To clarify the role of miR-33 in remodeling hearts, we investigated the responses to pressure overload by transverse aortic constriction in miR-33-deficient (knockout [KO]) mice. When mice were subjected to transverse aortic constriction, miR-33 expression levels were significantly upregulated in wild-type left ventricles. There was no difference in hypertrophic responses between wild-type and miR-33KO hearts, whereas cardiac fibrosis was ameliorated in miR-33KO hearts compared with wild-type hearts. Despite the ameliorated cardiac fibrosis, miR-33KO mice showed impaired systolic function after transverse aortic constriction. We also found that cardiac fibroblasts were mainly responsible for miR-33 expression in the heart. Deficiency of miR-33 impaired cardiac fibroblast proliferation, which was considered to be caused by altered lipid raft cholesterol content. Moreover, cardiac fibroblast-specific miR-33-deficient mice also showed decreased cardiac fibrosis induced by transverse aortic constriction as systemic miR-33KO mice.Our results demonstrate that miR-33 is involved in cardiac remodeling, and it preserves lipid raft cholesterol content in fibroblasts and maintains adaptive fibrotic responses in the remodeling heart.
Lenalidomide Followed with Donor Lymphocytes Infusion (DLI) After Allogeneic Stem-Cell Transplantation (Allo-SCT) with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma
Authors: Jean El-Cheikh, Roberto Crocchiolo, Patrick Ladaique, Sabine Furst, Luca Castagna, Catherine Faucher, Angela Granata, Claire Oudin, Claude Lemarie, Boris Calmels, Anne Marie Stoppa, jean Marc schiano De Colella, Segolene Duran, Christian Chabannon, Didier Blaise
Journal: Blood (2011)
Downregulation of Dicer1 Promotes Cellular Senescence and Decreases the Differentiation and Stem Cell-Supporting Capacities of MSCs in Patients with Myelodysplastic Syndrome
Authors: Youshan Zhao, Dong Wu, Chengming Fei, Juan Guo, Shucheng Gu, Feng Xu, Zheng Zhang, Chunkang Chang, Xiao Li
Journal: Blood (2014)
<i>KIT, DOG1, PDGFR</i>, and <i>IGFR1</i> gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Authors: J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero
Journal: Journal of Clinical Oncology (2011)

10047 Background: There are scarce and controversial findings published on KNGL series. One of the largest analyzing 26 KNGL found two distinct subsets according to immunostaining (IS): DOG1+ cases were gastric with PDGFRA mutations and DOG1- cases were gastric or intestinal both alike and usually wild type. We analyzed expression of genes known to be implicated in GIST as well as miRNA221/222 (negative regulators of KIT) to attempt a better characterization of KNGL and to assess their prognostic value in a KNGL series of 32 patients. Methods: The expression level of KIT, PDGFRA, DOG1, IGF1R, miRNA-221 and miRNA-222 was determined by qRT-PCR. We also analyzed the KIT and PDGRA mutations, DOG1 IS along with clinical and pathological data. Differences in metastases free and overall survival were calculated for the various prognostic factors using Log-rank test. Results: The M/F rate was 16/16 and the median age was 62 y. With a median follow-up of 92 months, 14 events of metastases were registered. Hierarchical cluster analyses obtained from gene expression data identified two distinct groups: Group I, had an overexpression of KIT, DOG1 and PDGFRA, and underexpression of IGF1R; with predominance of epitheliod gastric cases, DOG1 + IS and PDGFRA mutations. On the contrary, group II had overexpression of IGF1R and underexpression of KIT, DOG1 and PDGFRA; most cases were non-gastric with DOG1 - IS and KIT mutated or wild type. Group II had a significant worse prognosis for both metastasis free (p= 0.028) and overall survival (p=0.013). The expression of miRNAs was lower in a subset of 9 cKIT + cases compared with this KNGL series (p =0.057 for miRNA221 and p<0.001 for miRNA222). Interestingly, the overall survival was significantly worse in cases with higher expression of miRNA221 (p =0.028) or miRNA222 (p=0.014) in the KNGL series. Conclusions: Our results identify the existence of two distinct subsets of KNGL cases also at gene expression level with a different prognostic value. Increased levels of miRNA-221/222 could explain the absence of protein expression of most of such cases. Finally, the fact of worse survival associated to higher miRNA 221/222 expression level deserves further investigation.
How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort
Authors: Arianna Masciulli, Tiziano Barbui, Rosa Maria Marfisi, Riccardo Cavazzina, Guido Finazzi, Monia Lunghi, Alessia Tieghi, Roberto Latagliata, Valerio De Stefano, Rossella Cacciola, Caterina Musolino, Marco Ruggeri, Emilio Usala, Giorgina Specchia, Elisa Rumi, Maria Luigia Randi, Alessandra Iurlo, Alessandro M. Vannucchi, Davide Rapezzi, Ilaria Scortechini, Francesca Lunghi, Maria Carmen Martorelli, Daniela Cilloni, Michele Nobile, Sergio Siragusa, Simone Santini, Elena Elli, Giuseppe Visani, Giovanni Quarta, Antonio Spadea, Roberto Marchioli
Journal: Blood (2012)
Selectively T Cell Depleted Allografts From HLA-Matched Sibling Donors Followed by Low-Dose Post Transplant Immunosuppression to Limit Disease Relapse In Patients with Hematological Malignancies
Authors: Zachariah A. McIver, Stephan Mielke, Aarthi Shenoy, Vicki Fellows, David Stroncek, Susan Leitman, Richard Childs, Minoo Battiwalla, Eleftheria K. Koklanaris, Janice Haggerty, Bipin N. Savani, Katy Rezvani, A. John Barrett
Journal: Blood (2010)
Identification of IL-17F/frequent exacerbator endotype in asthma
Authors: Fabio L.M. Ricciardolo, Valentina Sorbello, Anna Folino, Fabio Gallo, Gian Mario Massaglia, Gabriella Favatà, Salvatore Conticello, Davide Vallese, Federica Gani, Mario Malerba, Gert Folkerts, Giovanni Rolla, Mirella Profita, Thais Mauad, Antonino Di Stefano, Giorgio Ciprandi
Journal: Journal of Allergy and Clinical Immunology (2016)